Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Verona Pharma Plc ADR shares valued at $922,000 were sold by Fisher Andrew on Jun 16 ’25. At $11.53 per share, Fisher Andrew sold 80,000 shares. The insider’s holdings dropped to 359,999 shares worth approximately $32.43 million following the completion of this transaction.
Also, Hahn Mark W sold 400,000 shares, netting a total of over 4,560,360 in proceeds. Following the sale of shares at $11.40 each, the insider now holds 12,278,992 shares.
Before that, ZACCARDELLI DAVID had sold 400,000 shares from its account. In a trade valued at $4,560,520, the President and CEO traded Verona Pharma Plc ADR shares for $11.40 each. Upon closing the transaction, the insider’s holdings decreased to 400,000 shares, worth approximately $1.19 billion.
As published in their initiating research note from Wolfe Research on July 01, 2025, Verona Pharma Plc ADR [VRNA] has been an Outperform and the price target has been revised to $170. Analysts at TD Cowen started covering the stock with ‘”a Buy”‘ outlook in a report released in late April. As of April 21, 2025, Cantor Fitzgerald has initiated its “an Overweight” rating for VRNA. Earlier on January 10, 2025, ROTH MKM initiated its rating. Their recommendation was “a Buy” for VRNA stock.
Analyzing VRNA Stock Performance
On last trading session,, Verona Pharma Plc ADR [NASDAQ: VRNA] plunged -0.44% to $90.08. The stock’s lowest price that day was $89.1, but it reached a high of $93.39 in the same session. During the last five days, there has been a drop of approximately -5.29%. Over the course of the year, Verona Pharma Plc ADR shares have jumped approximately 522.96%. Shares of the company reached a 52-week high of $99.01 on 06/24/25 and a 52-week low of $43.44 on 01/10/25.
Support And Resistance Levels for Verona Pharma Plc ADR (VRNA)
According to the 24-hour chart, there is a support level at 88.32, which, if violated, would cause prices to drop to 86.57. In the upper region, resistance lies at 92.61. The next price resistance is at 95.15. RSI (Relative Strength Index) is 55.59 on the 14-day chart, showing neutral technical sentiment.
Is Verona Pharma Plc ADR subject to short interest?
Stocks of Verona Pharma Plc ADR saw a sharp rise in short interest on 2025-06-13 jumping by 0.35 million shares to 8.42 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 8.07 million shares. A jump of 4.13% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.19 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.19.
Which companies own the most shares of Verona Pharma Plc ADR (VRNA)?
In terms of Verona Pharma Plc ADR share price expectations, FactSet research, analysts set an average price target of 81.5 in the next 12 months, down nearly -9.92% from the previous closing price of $90.48. Analysts anticipate Verona Pharma Plc ADR stock to reach 170 by 2025, with the lowest price target being 74. In spite of this, 7 analysts ranked Verona Pharma Plc ADR stock as Buy at the end of 2025. On October 03, 2024, Wells Fargo assigned a price target of “an Overweight” to the stock and initiated coverage with a $50.
